Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WILLOW long-term extension of enpatoran in cutaneous and systemic lupus
MOH_2023-02-26_012377Phase 2Active, not recruiting
- Sponsor
- Merck KGaA
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, double-blind trial of enpatoran in subacute cutaneous lupus erythematosus (SCLE), discoid lupus erythematosus (DLE) and systemic lupus erythematosus (SLE) (3 arms), sponsored by Merck KGaA. Started Nov 2022; status: active, not recruiting.
02
Drugs
enpatoran
03
Conditions
subacute cutaneous lupus erythematosus (SCLE)discoid lupus erythematosus (DLE)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on MOH_2023-02-26_012377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-02-26_012377.